Benitec Biopharma

BNTCPhase 2

Hayward, United Statesbenitec.com

Benitec Biopharma Inc. is a clinical-stage biotech focused on developing transformative, single-administration genetic medicines for chronic and life-threatening conditions. Its proprietary ddRNAi platform is designed to permanently silence disease-causing genes by integrating RNAi into a gene therapy vector. The company's most advanced program, BB-301 for OPMD, is in Phase 1b/2a trials and has shown positive interim results, positioning Benitec as a leader in next-generation gene silencing therapeutics.

Market Cap

$376.1M

Focus

RNA & Gene Therapy

BNTC · Stock Price

USD 10.9824.38 (-68.95%)

Historical price data

AI Company Overview

Technology Platform

DNA-directed RNA interference (ddRNAi), a platform combining AAV-based gene therapy delivery with encoded short hairpin RNA (shRNA) to achieve sustained, single-administration silencing of disease-causing genes.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
BB-401	Head and Neck Squamous Cell Carcinoma	Phase 2

Funding History

Total raised: $10M

PIPE$10MUndisclosedAug 15, 2015

IPOUndisclosedUndisclosedJun 30, 2004

Opportunities

Validating the ddRNAi platform with BB-301 in OPMD opens the door to applying the technology to a wide range of other monogenic diseases, significantly expanding the company's pipeline and market potential.

As the only clinical-stage therapy for OPMD, BB-301 has a clear path to orphan drug designation and a niche market with high unmet need.

Risk Factors

Key risks include clinical trial failure or safety issues with BB-301, the unproven long-term durability and safety of the ddRNAi platform in humans, and the ongoing need for significant capital to fund development, which may lead to shareholder dilution.

Competition from emerging gene editing technologies also poses a long-term threat.

Competitive Landscape

Benitec's primary competition comes from companies using transient RNAi (e.g., Alnylam) or antisense oligonucleotides, which require repeated dosing. Its key differentiation is the aim for one-time, durable gene silencing. In OPMD specifically, it currently faces no direct clinical-stage competition.

Publications

Patents

Pipeline